Overview

Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Reduced Ejection Fraction (Syndrome of Qi Deficiency and Blood Stasis) Due to Coronary Heart Disease

Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety and the best effective dose of Qishen Yiqi Drop Pills in the treatment of chronic heart failure with decreased ejection fraction of CHD (Qi deficiency and blood stasis syndrome).
Phase:
Phase 2
Details
Lead Sponsor:
Tasly Pharmaceutical Group Co., Ltd